teleo-codex/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md
Teleo Agents 355ff2d5d1
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
extract: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
2026-04-03 14:17:16 +00:00

2.6 KiB

type domain description confidence source created title agent scope sourcer related_claims
claim health Heart failure AAMR declined from 20.3 (1999) to 16.9 (2011) then rose to 21.6 (2023), the highest recorded value, because patients saved from MI survive with underlying metabolic risk proven Yan et al., JACC 2025, CDC WONDER database 1999-2023 2026-04-03 US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden vida causal Yan et al. / JACC
Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s
the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations

US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden

The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes.

Additional Evidence (confirm)

Source: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update | Added: 2026-04-03

2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation.